The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1403
Linaclotide (Linzess) for Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Linaclotide (lin´´ a kloe´ tide; Linzess – Ironwood/Forest), a guanylate cyclase-C receptor agonist, was recently approved by the FDA for oral treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. It is the second drug approved for this indication; lubiprostone (Amitiza), a metabolite of prostaglandin E1, was the first.1,2

MECHANISM OF ACTION — Linaclotide is a 14-amino acid synthetic peptide that activates guanylate cyclase-C receptors on the luminal surface of the intestinal epithelium, increasing cGMP within the intestinal epithelial cells. This results in activation of the CFTR ion channel, increasing the secretion of chloride and bicarbonate ions into the intestinal lumen, increasing intraluminal fluid and accelerating intestinal transit.

CLINICAL STUDIES — Chronic ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Linaclotide (Linzess) for Constipation
Article code: 1403b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian